(5aR,5bS,7aS,10bR)-8-(5-methoxypyridin-3-yl)-5a,7a-dimethyl-4,5,5a,5b,6,7,7a,10b,11,12-decahydrocyclopenta[5,6]naphtho[1,2-d]azepin-2(3H)-one

ID: ALA3919772

PubChem CID: 68086981

Max Phase: Preclinical

Molecular Formula: C25H30N2O2

Molecular Weight: 390.53

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COc1cncc(C2=CC=C3[C@@H]4CCC5=CC(=O)NCC[C@]5(C)[C@H]4CC[C@]23C)c1

Standard InChI:  InChI=1S/C25H30N2O2/c1-24-10-11-27-23(28)13-17(24)4-5-19-21-7-6-20(25(21,2)9-8-22(19)24)16-12-18(29-3)15-26-14-16/h6-7,12-15,19,22H,4-5,8-11H2,1-3H3,(H,27,28)/t19-,22-,24-,25+/m0/s1

Standard InChI Key:  ZFXBUQVIGZLFKO-JFTIDPPCSA-N

Molfile:  

     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
    6.0708  -18.4677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8463  -19.2576    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0748  -19.5378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1030  -20.3518    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4070  -20.7849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4342  -21.6039    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7433  -22.0339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0252  -21.6449    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9961  -20.8341    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6870  -20.4041    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6598  -19.5851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3558  -19.1519    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6870  -21.2232    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    2.3353  -20.3420    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5497  -20.5547    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2213  -21.3013    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5993  -22.0130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3979  -22.1952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1918  -22.7208    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.9961  -20.0149    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4070  -19.9658    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    5.8847  -20.5785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3444  -19.9016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1334  -18.7203    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5018  -17.8776    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7294  -17.0951    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5223  -16.8987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0891  -17.4828    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.8683  -18.2701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1633  -16.5058    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.3906  -15.7209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  3  2  1  0
  4  3  1  0
  5  4  1  0
  6  5  1  0
  7  6  1  0
  8  7  1  0
  9  8  1  0
  9 10  1  0
 11 10  1  0
 12 11  1  0
  3 12  1  0
  5 10  1  0
 10 13  1  6
  9 14  1  0
 15 14  1  0
 16 15  1  0
 17 16  1  0
 18 17  1  0
  8 18  2  0
 17 19  2  0
  9 20  1  1
  5 21  1  1
  4 22  2  0
 23 22  1  0
  2 23  2  0
  3 24  1  1
 25  1  2  0
 26 25  1  0
 27 26  2  0
 28 27  1  0
 29 28  2  0
  1 29  1  0
 26 30  1  0
 30 31  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA3919772

   (3bR,10aR,10bS,12aS)-1-(5-methoxypyridin-3-yl)-10a,12a-dimethyl-4,5,8,9,10,10b,11,12-octahydro-3bH-indeno[4,5-i][3]benzazepin-7-one

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 390.53

Molecular Weight (Monoisotopic): 390.2307

AlogP: 4.69

#Rotatable Bonds: 2

Polar Surface Area: 51.22

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 4.46

CX LogP: 2.79

CX LogD: 2.79

Aromatic Rings: 1

Heavy Atoms: 29

QED Weighted: 0.80

Np Likeness Score: 1.60

References

1.  (2013)  C-17-heteroaryl steroidal compounds as inhibitors of CYP11B, CYP17, and/or CYP21, 

2. Ling, Y Z YZ and 5 more authors.  1997-09-26  17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha).  [PMID:9379450]

3. Hartmann, R W RW and 5 more authors.  2000-11-02  Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.  [PMID:11063622]

4. Recanatini, M M and 9 more authors.  2001-03-01  A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.  [PMID:11262078]

5. Clement, Omoshile O OO and 6 more authors.  2003-06-05  Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.  [PMID:12773039]

6. Handratta, Venkatesh D VD and 10 more authors.  2005-04-21  Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.  [PMID:15828836]

7. Voets, Marieke M and 7 more authors.  2005-10-20  Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.  [PMID:16220979]

8. Pinto-Bazurco Mendieta, Mariano A E MA and 5 more authors.  2008-08-28  Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.  [PMID:18672868]

9. Hu, Qingzhong Q and 8 more authors.  2008-08-15  Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.  [PMID:18674917]

10. Hille, Ulrike E UE and 7 more authors.  2009-07  Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.  [PMID:19211174]

11. Hu, Qingzhong Q, Yin, Lina L, Jagusch, Carsten C, Hille, Ulrike E UE and Hartmann, Rolf W RW.  2010-07-08  Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.  [PMID:20550118]

12. Hu, Qingzhong Q, Jagusch, Carsten C, Hille, Ulrike E UE, Haupenthal, Jörg J and Hartmann, Rolf W RW.  2010-08-12  Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.  [PMID:20684610]

13. Yin, Lina L and 5 more authors.  2012-07-26  Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.  [PMID:22788843]

14. Purushottamachar, Puranik P and 8 more authors.  2013-06-27  Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.  [PMID:23713567]

15. Pinto-Bazurco Mendieta, Mariano A E MA, Hu, Qingzhong Q, Engel, Matthias M and Hartmann, Rolf W RW.  2013-08-08  Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.  [PMID:23859149]

16. Rafferty, Stephen W SW, Eisner, Joel R JR, Moore, William R WR, Schotzinger, Robert J RJ and Hoekstra, William J WJ.  2014-06-01  Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.  [PMID:24775307]

17. Njar, Vincent C O VC and Brodie, Angela M H AM.  2015-03-12  Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.  [PMID:25591066]

18. Huang, Audris A and 21 more authors.  2016-01-14  Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.  [PMID:26819663]

19. Blass, Benjamin E BE and 18 more authors.  2016-12-01  Design, synthesis, and evaluation of (2S,4R)-Ketoconazole sulfonamide analogs as potential treatments for Metabolic Syndrome.  [PMID:27789139]

20. Wang, Mingliang M and 6 more authors.  2017-05-26  Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.  [PMID:28350999]

21. Fehl, Charlie C and 5 more authors.  2018-06-14  Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.  [PMID:29792703]

22. Blass, Benjamin E BE and 20 more authors.  2018-07-15  Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17α-hydroxylase-C17,20-lyase (Cyp17).  [PMID:29803730]

23. Child, Stella A and Guengerich, F Peter.  2020-06-25  Multistep Binding of the Non-Steroidal Inhibitors Orteronel and Seviteronel to Human Cytochrome P450 17A1 and Relevance to Inhibition of Enzyme Activity.  [PMID:32223238]

Source

Source(1):

• Patent Bioactivity Data